Tirzepatide

Tirzepatide is a synthetic, long-acting peptide engineered to act as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual incretin receptor activity distinguishes it from traditional single-pathway GLP-1 receptor agonists and results in amplified downstream signaling in metabolic tissues. By leveraging the complementary physiology of GIP and GLP-1, tirzepatide enhances insulin secretion in a glucose-dependent manner while simultaneously modulating glucagon release, contributing to improved glycemic control.

At the cellular level, tirzepatide activates G protein–coupled receptor pathways that increase intracellular cyclic AMP (cAMP), thereby enhancing pancreatic β-cell responsiveness to elevated plasma glucose. In addition to pancreatic effects, it exerts significant influence on central appetite regulation through hypothalamic pathways, leading to reduced caloric intake and body weight. Tirzepatide also slows gastric emptying, which contributes to postprandial glucose control, and may improve insulin sensitivity in peripheral tissues such as skeletal muscle and adipose tissue.

Pharmacokinetically, tirzepatide is modified with a fatty diacid moiety that facilitates reversible binding to albumin, extending its half-life and enabling once-weekly subcutaneous administration. Clinical studies have demonstrated substantial reductions in glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes and obesity. Its pleiotropic metabolic effects, including improvements in lipid profiles and potential cardiovascular risk markers, are an area of ongoing investigation, positioning tirzepatide as a significant advancement in incretin-based therapeutics.